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Purpose: This study evaluates intraocular pressure (IOP) elevation secondary to intravitreal 
injection of triamcinolone acetonide (IVTA) and discusses its management.
Methods: The records of 175 patients who underwent IVTA treatment and regular eye exami-
nations in the period 2003–2006 were reviewed. One hundred and twenty-two of these patients 
were included in the study, of which 147 eyes that received IVTA (4 mg/0.1 ml) were followed 
for at least 9 months. Mean IOPs observed after IVTA injection as well as IOP elevations 
deﬁ  ned as moderate (5 mm Hg), important (10 mm Hg) and severe (25 mm Hg) during 
the follow-up period were evaluated and compared statistically.
Results: Overall, the mean IOPs following IVTA injection were statistically signiﬁ  cantly 
higher than the preinjection IOP (15.8 ± 2.6), after the ﬁ  rst hour (17.7 ± 2.9), the ﬁ  rst week 
(18.7 ± 4.1), the ﬁ  rst month (19.6 ± 6.2), the second month (19.1 ± 6.1), the third month (18.0 ± 
4.1), the sixth month (17.3 ± 4.0), and the ninth month (17.0 ± 2.7), but not after the ﬁ  rst day 
(16.3 ± 7.6). Important IOP elevations were observed mostly in the ﬁ  rst (17.7%) and second 
months (10.2%). In 40 (27.7%) eyes, topical antiglaucomatous therapy was needed and 7 later 
required surgical intervention to lower the IOP. Of the remaining 33 eyes, topical treatment 
was continued in 14 (9.5%) because of IOPs 20 mm Hg.
Conclusion: The persistence of IOP elevation beyond the IVTA clearance period and the 
development of intractable secondary glaucoma requiring surgical intervention substantiate 
the need for careful consideration of IVTA indication and follow-up.
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Introduction
Over the past 5 years, intravitreal triamcinolone acetonide (IVTA) injection has 
emerged as an important and effective treatment modality for various intraocular 
pathologies (Jonas 2005; Jonas et al 2005). However, because the most common side 
effect of IVTA treatment is elevation of the intraocular pressure (IOP), the incidence 
of steroid-induced glaucoma has also increased.
Steroid-induced glaucoma has been well recognized since the independent studies of 
Armaly and Becker in the 1960s (Skuta 1996; Jones 2006). Corticosteroids are known 
to elevate the IOP by all routes of administration, but topical use of potent steroids 
causes IOP elevation in one-third of all eyes treated (Skuta 1996). The steroids indi-
rectly cause a rise in IOP by promoting excessive deposition of extracellular material 
in the trabecular meshwork (TM), thus reducing the outﬂ  ow of aqueous humor (Skuta 
1996; Jones 2006). Armaly reported that 5% of adult patients were high-responders 
(increases in IOP 15 mm Hg), and as many as 3% of steroid responders may experi-
ence persistent and irreversible IOP elevation (Skuta 1996; Jones 2006).
The pressure increases induced by IVTA tend to be more acute and signiﬁ  cant than 
those caused by other modes of administration. However, a recent report showed that Clinical Ophthalmology 2008:2(1) 168
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the ultrastuctural changes in the TM after IVTA treatment 
are similar to those resulting from hypertension after topical 
corticosteroid treatment (Kubota 2006). Rare causes of IOP 
elevation related to IVTA injection have included an early 
and rapid rise in IOP related to mechanical obstruction of the 
trabeculum by triamcinolone particles in pseudophakic eyes, 
and cases of angle closure and malignant glaucoma (Jonas 
et al 2003; Singh et al 2004; Sivaprasad et al 2006).
The serious rise in IOP due to IVTA can usually be 
managed successfully with topical medications. However, 
in a small percentage of eyes the hypertension may be 
uncontrollable with topical treatment; in such cases, surgical 
procedures to reduce the IOP should be carried out (Jonas 
2005; Jonas et al 2005).
In this prospective study of patients treated with IVTA 
injections, we report our ﬁ  ndings on the elevated IOP levels 
and the development of secondary chronic open angle glau-
coma. We also discuss the treatment strategies and options 
we used in the management of these cases.
Materials and methods
The records of 175 patients who underwent IVTA treatment 
in the period 2003–2006 were reviewed. Fifty-three of these 
patients failed their regular eye examinations and were 
excluded from the study.
Eyes with known primary or secondary glaucoma were not 
taken into the study. Gonioscopic examination was done regu-
larly in all patients before and after the IVTA injection. Patients 
with narrow or closed angles were not injected with IVTA, 
and during the follow-up we observed neither angle closure 
nor angle neovascularization development in any eye.
The IVTA injections were carried out by two vitreoretinal 
surgeons (M.S.K. and G.G.) under aseptic conditions. 
After topical anesthesia and asepsia by povidone-iodine, 
4 mg/0.1 mL of triamcinolone was injected with a 27 gauge 
needle 3.5 to 4 mm from the limbus inferotemporally.
Regular eye examinations were done during the ﬁ  rst 
hour and the ﬁ  rst day, and then one week, one month, two 
months, three months, six months, and nine months after the 
injection. The IOP measurements were done routinely using 
a Goldmann applanation tonometer, but in rare instances a 
Tono-pen tonometer was also used.
After the first observation of IOP elevation, if the 
pressure remained above 25 mm Hg at any follow-up 
examination, a topical medication to lower the IOP was 
considered. Dorzolamide, brinzolamide, and the combination 
of dorzolamide–timolol were the ﬁ  rst choices for the topical 
treatment, but brimonidine was added when it was needed.
The preoperative IOP was statistically compared with the 
postinjection IOPs at different time points. The evaluation was 
made according to the magnitude of the IOP elevation and the 
rate at which the IOP dropped to below 21 mm Hg in eyes 
treated with topical medications. Moderate and important IOP 
elevations above the preoperative baseline were deﬁ  ned as 
5 mm Hg and 10 mm Hg, respectively, based on previous 
studies. The need and the type of surgery performed to lower 
the IOP in the intractable cases (25 mm Hg) were noted. The 
type of surgery undertaken was decided based on the severity 
of the IOP elevation and the comorbidity of the eye.
Statistical analyses were done using SPSS software. 
Paired t test was used to compare the mean IOP values at 
different time intervals. A p value of 0.05 was considered 
statistically signiﬁ  cant.
Results
One hundred and forty-seven eyes of 122 patients, 72 women 
and 50 men, which could be followed regularly for at least 9 
months, were included in the study. The mean age of the patients 
was 58.4 ± 9.1 years (range 36–78). Patients with previous 
glaucoma did not receive IVTA treatment. The main indication 
for IVTA was macular edema caused by diabetic retinopathy in 
121 eyes, retinal venous occlusion in 22 eyes, uveitis in 2 eyes, 
and subretinal choroidal neovascularization in 2 eyes. Twenty-
one eyes without a previous important increase in IOP received 
a second IVTA injection for persistent or recurrent diabetic 
macular edema without any subsequent IOP increase.
Besides the IOP elevation, other complications we 
observed following IVTA injection were secondary cataract 
development in 14 eyes, pseudohypopyon in 3 eyes, and 
bacterial endophthalmitis in 1 eye.
The mean IOPs and the IOP elevations at different follow-
up intervals are shown in Table 1 and Table 2. All the eyes 
including those under topical treatment are included in the 
analyses.
In 40 eyes (27.2%), topical treatment was initiated to 
reduce the IOP when persistent elevation above 25 mm Hg 
was observed over one month in weekly examinations after 
the ﬁ  rst observation of IOP 25 mm Hg. Subsequent surgical 
treatment was needed in 7 of the 40 (4.7%) to reduce high 
IOP levels that were refractory to maximal medical therapy 
with 2 or 3 antiglaucomatous drugs. In the remaining 33 eyes, 
topical treatments were stopped in 19 (13%) and continued 
in 14 (9.5%) for at least nine months postinjection. Topical 
treatments were discontinued depending on the IOP level; 
an IOP 20 mm Hg despite treatment was considered an 
indication for continuing treatment.Clinical Ophthalmology 2008:2(1) 169
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Surgery for lowering the IOP was required for 7 (4.7%) of 
the 147 eyes. The operations performed were trabeculectomy 
in 3, pars plana vitrectomy in 2, and cyclophotocoagulation 
in 2 eyes. All 7 eyes had an IOP 32 mm Hg despite medical 
treatment. In one eye, cyclophotocoagulation was repeated 
1 month after the ﬁ  rst procedure because of an inadequate 
reduction in IOP. In all 7 eyes the IOP returned to below 
21 mm Hg during the follow-up period after surgery.
When we compared the levels of IOP increases between 
the subgroups, we found that in the retinal venous occlusion 
cases (22 eyes) the IOP elevation was more pronounced 
compared with that of the diabetic retinopathy eyes, from the 
ﬁ  rst month until the sixth month. Repeated IVTA injections 
in 21 eyes did not result in an increase in IOP.
Discussion
Intravitreal injection of long-acting steroids is indicated for 
the treatment of edematous, inﬂ  ammatory, and neovascular 
intraocular diseases. The prolonged effect of triamcinolone 
is mainly due to its low water-solubility. Accordingly, 
measurable concentrations of triamcinolone can persist for 
at least 3 or 18 months after intravitreal injection of 4 mg 
or 20–25 mg, respectively (Beer et al 2003; Heatley et al 
2006). Triamcinolone was detected 2.75 to 5 months after 
intravitreal injection of 4 mg (Mason et al 2004).
In our series, following IVTA injection, statistically 
signiﬁ  cant increases in IOP levels were observed from the 
ﬁ  rst week until the ninth month postinjection. Important IOP 
increases were ﬁ  rst observed in the ﬁ  rst week postinjection 
and then most frequently in the ﬁ  rst month; thereafter the 
levels gradually declined due to the effect of the topical treat-
ments and also probably to the clearance of triamcinolone 
from the vitreous cavity with time. The mean postinjection 
IOP measurements showed highly statistically signiﬁ  cant 
differences (p  0.0001) at all time points, except in ﬁ  rst 
day, compared with the baseline IOP. Surprisingly, the IOP 
levels during the ﬁ  rst week after the injection were statisti-
cally signiﬁ  cantly higher than the preinjection IOP, but only 
2.7% of the eyes showed important IOP elevations.
In other studies, approximately a third to a half of all 
patients receiving IVTA treatment experienced an increase 
in IOP to above 21 mm Hg (Wingate 1999; Bakri et al 2003; 
Smithen et al 2004; Jonas et al 2006; Kocabora et al 2007).
This prevalence may depend on several factors, includ-
ing how the increase is deﬁ  ned, the dosage of IVTA, the 
baseline IOP, the age of the patient, and the type of concur-
rent eye disease. The high dosage used by Jonas (2005) was 
associated with a higher rate of IOP increase lasting up to 
9 months longer than observed for the 4 mg dose. A recent 
study reported that increases in IOP levels were mostly seen 
in relatively young patients with uveitis who had received a 
high dose of IVTA (Jonas 2007).
The standard dose of IVTA we used was 4 mg in 0.1 ml. 
The signiﬁ  cant increase in IOP levels observed in the ﬁ  rst 
hour in our cases was probably due to the volume-effect of the 
injected IVTA; only 8.8% of the eyes showed a moderately 
elevated IOP in the ﬁ  rst hour postinjection.
Gillies and colleagues (2006) reported an incidence of 
IOP elevation (increased by 5 mm Hg) of 68%, signiﬁ  -
cantly higher than observed in previous studies, and rates 
of topical treatment and glaucoma surgery of 44% and 6%, 
respectively.
In our series, the rates of topical treatment and surgery 
for reducing high IOP were 27% and 4.7%, respectively. 
Considering the high concentration of intraocular triamcino-
lone and predisposing factors such as diabetes and arterial 
hypertension (Becker et al 1966; Langman et al 2005), these 
important rates were not surprising. The earliest topical 
Table 1 Mean IOP values at different follow-up times
Pre-IVTA  1 hour  1 day  1 week  1 month  2 month  3 month  6 month  9 month
15.8 ± 2.62  17.68 ± 2.92  16.26 ± 7.56  18.68 ± 4.06  19.6 ± 6.22  19.07 ± 6.12  18.02 ± 4.12  17.33 ± 4.02  16.96 ± 2.67
  0.0001  =0.1426  0.0001  0.0001  0.0001  0.0001  =0.0001  =0.0002
Abbreviations: IOP, intraocular pressure; IVTA, intravitreal injection of triamcinolone acetonide.
Table 2 Magnitudes of IOP increases at different follow-up times
IOP increase  Pre-IVTA  1 hour  1 day  1 week  1 month  2 month  3 month  6 month  9 month
5 mm Hg  –  13 (8.8%)  7 (4.7%)  35 (23.8%)  22 (15%)  15 (10.2%)  22 (15%)  21 (14.2%)  21 (14.2%)
10 mm Hg  –  0 (0%)  0 (0%)  4 (2.7%)  26 (17.7%)  15 (10.2%)  8 (5.4%)  7 (4.7%)  3 (2%)
IOP 25 mm Hg  –  0 (0%)  0 (0%)  14 (9.5%)  28 (19%)  18 (12.2%)  6 (4.1%)  5 (3.4%)  3 (2%)
Abbreviations: IOP, intraocular pressure; IVTA, intravitreal injection of triamcinolone acetonide.Clinical Ophthalmology 2008:2(1) 170
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treatment was started after the ﬁ  rst month and the earliest 
surgery was performed after the second month.
The persistence of IOP elevation despite cessation of 
steroid treatment has been known for a long time (Spaeth et al 
1977). The work of Armaly and Becker suggests that 5%–6% 
of the population will likely be high responders who develop 
important IOP elevations early after steroid use, apart from 
diabetic patients who are also known to be predisposed to 
IOP rises after steroid treatment (Skuta 1996). In our study, 
despite topical treatment, a surprisingly high IOP persisted 
in 9.5% of the eyes beyond 9 months; we considered these 
cases as secondary open angle glaucoma development due 
to IVTA. Unless most of our patients were diabetic, this rate 
is very high.
Severe and intractable IOP elevations, despite maximally 
tolerated medical therapy after IVTA, were reported to occur 
in some eyes, especially those with retinal vein occlusions 
(Kaushik et al 2004; Yang et al 2005; Quiram et al 2006). The 
reported treatment methods for secondary ocular hyperten-
sion after IVTA were argon laser trabeculoplasty, selective 
laser trabeculoplasty, trabeculectomy, drainage devices, and 
pars plana vitrectomy (Agrawal et al 2004; Kaushik et al 
2004; Yang et al 2005; Pizzimenti et al 2006; Quiram et al 
2006; Sivaprasad et al 2006; Viola et al 2006).
In our series of eyes, intractable glaucoma needing 
surgical intervention was observed in 7 eyes. The primary 
pathology was retinal venous occlusions in 2 of these eyes 
and diabetic retinopathy in 5. We carried out trabeculec-
tomies in 3 eyes and pars plana vitrectomies in 2 eyes all 
with severe IOP increases 40 mm Hg after the ﬁ  rst month. 
Cyclophotocoagulations were performed in 2 eyes with rela-
tively less severe IOP increases up to 32–35 mm Hg.
The persistence of IOP above 35 mm Hg for days and 
weeks increases the risk of damage to the optic disc as well 
as retinal vascular occlusion. Therefore, it is absolutely 
necessary to perform a surgical procedure to lower the IOP 
to normal levels.
The choice of surgical modality should be made accord-
ing to the magnitude of the IOP and the surgeon’s experience. 
Trabeculectomy can be the ﬁ  rst choice for the management of 
intractable ocular hypertension. Pars plana vitrectomy aims 
to decrease the IOP by removing intravitreal triamcinolone 
crystals, but it is a very aggressive way to reduce the IOP; 
therefore, the method should be limited to eyes that would 
receive additional beneﬁ  t from this surgery. Cyclophotoco-
agulation is another technique we used to reduce the IOP 
because it is easy to perform and has fewer complications 
than the aforementioned surgeries.
Two potential drugs, anecortave and mifepristone, for the 
treatment of steroid-induced glaucoma (Green et al 1989; 
Robin et al 2005) might obviate the need for surgical treat-
ment of triamcinolone-induced glaucoma.
The risk of secondary glaucoma needing permanent 
antiglaucomatous drug use and of a serious intractable 
IOP elevation requiring surgical intervention validate 
the necessity of a careful period of IVTA indication and 
follow up.
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